Latest Darbepoetin alfa Stories
THOUSAND OAKS, Calif., May 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from studies involving nine molecules in the Company's oncology portfolio will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4( )- 8, 2010 in Chicago. "Cancer is a complex disease that requires a comprehensive approach.
A new study helps dispel mounting confusion over the safety of blockbuster anemia drugs â€” erythropoiesis-stimulating agents â€” for people with kidney disease requiring dialysis, as federal regulators prepare to decide whether to impose additional restrictions on their use.
SILVER SPRING, Md., Feb 16 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs).
HORSHAM, Pa., Feb. 16 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. and Amgen Inc. today announced that the U.S.
THOUSAND OAKS, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) and Centocor Ortho Biotech Products, L.P., today announced that the U.S.
EXTON, Pa., Jan. 6 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the availability of its TreatmentTrendsÂ®: US Nephrology, EU Nephrology, and Canadian Nephrology publications.
An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising.
NEW YORK, Dec.
THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for NplateÂ® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Study highlights: - Risks of an anemia drug appear to outweigh its benefits among diabetic patients with kidney disease, anemia and a history of cardiovascular disease or stroke. - This first large, randomized, placebo-controlled trial finds drug raises hemoglobin levels and reverses anemia but does not improve patient cardiovascular outcomes. - Treatment with darbepoetin alfa in patients with type 2 diabetes, chronic kidney disease and moderate anemia doubled the risk of stroke compared to...
- Having no light.